Crizotinib versus chemotherapy: a real-world cost-effectiveness study in China.
Conclusion: Crizotinib could be an effective, and cost-effective first-line treatment for ALK positive advanced NSCLC with the MI coverage currently available in Chengdu, Sichuan Province, China.
PMID: 31958984 [PubMed - as supplied by publisher]
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Tags: J Comp Eff Res Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | China Health | General Medicine | Insurance | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pharmaceuticals | Study